|Articles|October 7, 2020
Findings from the LIO-1 Trial in advanced metastatic tumors
Author(s)Lindsey Carr, Editor
In a recent video from OncLive, Erika P. Hamilton, MD, highlights the initial findings from the ongoing phase 1b/2 LIO-trial in advanced metastatic tumors.
Advertisement
In the phase 1b portion of the study, researchers investigated the recommended dose of lucitanib in combination with nivolumab in patients with advanced solid tumors. Complete and partial responses were demonstrated in 17 patients who received the combination, according to Hamilton. Stable disease was also reported in 10 patients.
These data were seen across several tumor types, including those that do not typically respond to immunotherapy. The combination is now being evaluated further in phase 2 of the trial.
For more information, watch the video and visit
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal
2
Amber Watters, MD, on emergency preparedness and building a version program
3
Certolizumab pegol receives FDA BTD for adverse pregnancy outcomes in APS
4
Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo
5